Vor Biopharma INC Schedule 13D activist filings

RA Capital Management, L.P. and its affiliates have amended their Schedule 13D filing to report changes in beneficial ownership of VOR BIOPHARMA INC. common stock.

RA Capital Management reports a reduction in its beneficial ownership of Vor Biopharma Inc. common stock following recent open market sales.

RA Capital Management has disclosed a reduction in its beneficial ownership of VOR Biopharma Inc. following a series of open market sales.

RA Capital Management and its affiliates have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of VOR Biopharma Inc. common stock to 19.9%.

RA Capital Management and its affiliates have filed an amendment to their Schedule 13D, reporting a beneficial ownership of 19.9% in VOR Biopharma Inc. following recent stock sales.

RA Capital Management, L.P. and its affiliates filed an Amendment No. 13 to their Schedule 13D, reporting a beneficial ownership of 19.9% in VOR Biopharma Inc. due to an increase in outstanding shares.

RA Capital Management, L.P. and its affiliates have increased their beneficial ownership in VOR Biopharma Inc. to 19.9% by adjusting warrant exercise limitations.

Forbion Capital Partners entities have significantly increased their beneficial ownership in VOR Biopharma Inc. to 9.99% and appointed a General Partner to the board of directors.

RA Capital Management increased its beneficial ownership in VOR Biopharma to 14.0% through a $50 million private placement and appointed Andrew Levin to the board.

RA Capital Management, L.P. and its affiliates filed an Amendment No. 10 to their Schedule 13D, reporting a dilution of their beneficial ownership in VOR Biopharma Inc. to 9.9% following a recent public offering by the issuer.

RA Capital Management and its affiliates have significantly reduced their beneficial ownership in VOR BioPharma Inc. through recent open market sales.

RA Capital Management and its affiliates reported a reduction in their beneficial ownership of VOR Biopharma Inc. common stock to 17.3% through recent open market sales.

RA Capital Management and its affiliates reported a reduction in their beneficial ownership of VOR BioPharma Inc. common stock to 20.9% through recent open market sales.

Reprogrammed Interchange LLC and Reid Hoffman significantly reduced their beneficial ownership in Vor Biopharma Inc. through open market sales.

Reprogrammed Interchange LLC and Reid Hoffman significantly reduced their beneficial ownership in VOR BIOPHARMA INC. through open market sales, now holding 18.6% of common stock.

Reprogrammed Interchange LLC and Reid Hoffman have significantly reduced their beneficial ownership in VOR Biopharma Inc. to 20.1% through recent open market sales.

Reprogrammed Interchange LLC and Reid Hoffman significantly reduced their beneficial ownership in VOR Biopharma Inc. through open market sales, now holding 21.9% of common stock.

Reprogrammed Interchange LLC and Reid Hoffman reduced their beneficial ownership in VOR Biopharma Inc. to 23.3% following open market share sales.

RA Capital Management updated its beneficial ownership in VOR Biopharma to 29.0% following a 1-for-20 reverse stock split and announced a new board appointment.

Reprogrammed Interchange LLC and Reid Hoffman have reduced their stake in VOR Biopharma Inc. through recent open market sales, now holding 26.8% of common stock.

Reprogrammed Interchange LLC and Reid Hoffman reported significant open market sales of VOR Biopharma Inc. common stock, reducing their aggregate beneficial ownership to 28.0%.

Reprogrammed Interchange LLC and Reid Hoffman have reduced their beneficial ownership in VOR Biopharma Inc. through recent open market share sales.

5AM Ventures and its affiliated entities have substantially decreased their holdings in VOR Biopharma Inc., divesting nearly 2 million shares and ceasing to be a beneficial owner of more than five percent of the company's common stock.

RA Capital Management and its affiliates have significantly increased their beneficial ownership in VOR Biopharma Inc. to 31.8% through a $50 million private placement of pre-funded warrants, contingent on stockholder approval for share issuance and charter amendment.

Reprogrammed Interchange LLC and Reid Hoffman have acquired a 31.3% beneficial ownership stake in VOR Biopharma Inc. through a $38.75 million private placement, securing a board directorship and observer rights.